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Dear Editor,
Coagulation factor XI (FXI) is a member of the “contact path-
way” and is activated either intrinsically by coagulation factor XII 
(FXII) or by thrombin, which is produced by an extrinsic path-
way and plays an important role in hemostasis [1]. Factor XI de-
ficiency, also known as hemophilia C, is a predominantly auto-
somal recessive genetic bleeding disorder that was first reported 
in 1953 [2] and was found to be particularly prevalent in the 
Ashkenazi Jewish population [3]. The main clinical manifesta-
tion is damage-related or post-operational bleeding in the buc-
cal cavity, nasal cavity, tonsils, or urinary tract [4]. The F11 gene 
encodes the FXI protein, and mutations in the F11 gene have 
been found in patients with FXI deficiency. The F11 gene, lo-
cated on the long arm of chromosome 4 (4q35) with a genome 
size of 23 kb, consists of 15 exons and 14 introns [5]. Exon 1 
encodes the 5’-untranslated region, exon 2 encodes the signal 
peptide, and exons 3-15 are the region for encoding factor FXI 
protein [6]. FXI is synthesized as a homodimeric protein, and 
each FXI monomer consists of 4 N-terminal “apple domains” 
(A1-A4) and a C-terminal trypsin-like catalytic domain.
 According to the F11 gene mutation database (http://www.fac-
torxi.org), 192 mutations are associated with FXI deficiency. While 
the F283L missense mutation and the E117X nonsense mutation 
predominate in Ashkenazi Jews [7, 8], additional mutations have 
been reported in the non-Jewish populations. For example, the 
C38R missense mutation has been found to have a relatively high 
frequency in French Basques [9], whereas the C128X and Q88X 
nonsense mutations are more frequently reported in English Cau-
casians and in families from Western France, respectively [10, 
11]. The fact that some mutations, such as F283L and E117X, 
predominate in one population (i.e., the Ashkenazi Jewish popu-
lation) but have never been found in others (i.e., Asian popula-
tions) indicates that they are likely to be founder mutations. Al-
though large-scale population studies have not been carried out 
in a specific Asian population, smaller-scale studies have shown 
the prevalence of two nonsense mutations (Q226X and Q263X) 
in Japanese [12], Chinese [13], and Korean [14] patients. In this 
letter, we report the first case of a heterozygous mutation (C482W) 
in the F11 gene, resulting in a mild FXI deficiency in a Korean 
patient.
 A 14-yr-old male patient with intermittent epistaxis was admit-
ted to the hospital because of increased epistaxis frequency and 
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excessive blood flow. The patient did not have any abnormal 
medical history that would have indicated bleeding tendency, 
apart from being treated for allergic rhinitis. On admission, his 
vital signs were normal and the initial systemic examination did 
not uncover any bleeding problem or any other significant prob-
lem to be reported. The blood test results were as follows: leu-
kocyte count, 5.6×109/L; hemoglobin level, 15.9 g/dL; and 
platelet count, 215×109/L. The blood coagulation test showed 
normal prothrombin time (PT; 12.0 sec; reference range, 9.9-
12.3 sec) but prolonged activated partial thromboplastin time 
(aPTT; 45.9 sec, reference range, 20.9-35.0 sec). The thrombin 
time was normal (16.3 sec; reference range, 14.0-18.3 sec). 
When the patient’s plasma sample was mixed with the normal 
plasma sample (ratio 1:1), the prolonged aPTT was corrected to 
within the normal range. The level of von Willebrand factor was 
within the reference range. The lupus anticoagulant test results 
were negative. The activity levels of factors II through XII were 
within the reference ranges, whereas FXI showed slightly de-
creased activity (26%; reference range, 60-140%).
 The patient has an 11-yr-old sister who had no symptoms 
and no abnormal test results for the above described tests. The 
patient’s parents did not consent to be tested. The pedigree of 
the patient is shown in Fig. 1. Consent was obtained from the 
patient’s mother for the parent’s molecular genetic testing, and 
a whole blood sample was collected. The patient’s genomic 
DNA was extracted from the collected whole blood sample by 
using the Easy-DNA Kit (Invitrogen Corporation, Carlsbad, CA, 
USA). Exons 7, 8, 11, and 13 of the F11 gene were amplified by 
polymerase chain reaction (PCR) with the previously designed 
primer sets [14]. Direct sequencing of the amplified regions was 
performed by using the ABI Prism 3500dx automated genetic 
analyzer (Applied Biosystems, Foster City, CA, USA), the same 
primers that were used to amplify the 4 exons of the F11 gene 
by PCR, and the Big Dye Terminator Cycle Sequencing Ready 
Reaction Kit (Applied Biosystems). Sequencher software (Gene 
Codes Corporation, Ann Arbor, MI, USA) was used to compare 
the patient’s DNA sequences to the reference DNA sequence 
(GenBank accession number, NM_000128.3). The guidelines 
of the Human Genome Variation Society (HGVS) were used to 
identify the sequence variations.
 A heterozygous cytosine-to-guanine substitution, located at 
nucleotide 1,500 on exon 13, was identified in the patient’s F11 
gene. This mutation resulted in a cysteine-to-tryptophan amino 
acid change at codon 500 (p.Cys500Trp, according to HGVS 
nomenclature or Cys482Trp, according to the nomenclature 
suggested by Asakai et al. [6] (Fig. 2). Hereafter, we have used 
the conventional nomenclature method suggested by Asakai et 
al. [6] to refer to the identified amino acid change (Cys482Trp).
 The Cys482Trp missense mutation identified in our patient 
was previously reported in England [15], but has never been re-
ported in Korea. Only 17 cases of FXI deficiency (including the 
present case) have been confirmed by molecular and genetic 
testing in Korea [14, 16-18] (Table 1). Therefore, further testing 
and discovery of molecular lesions in the F11 gene in the Ko-
rean patients with FXI deficiency is needed to gain better under-
standing of founder mutations that are specific to this popula-
38 yr
14 yr
*
34 yr
11 yr
3.15 sec
68%
45.9 sec
26%
aPTT
FXI
Fig. 1. Pedigree of the family with factor XI deficiency. Genetic 
analysis was available for one family member (*).
Abbreviations: aPTT, activated partial thromboplastin time; FXI, factor XI ac-
tivity level.
Ref sequence C C C C C C CG GA AT T T T
Pro ProIle Cys Leu
Proband
Amino acid change*: Cys482Trp (C482W), Heterozygote
Fig. 2. Identification of the F11 gene mutation. Direct sequencing 
of the proband demonstrated a heterozygous mutation, c.1500C 
>G, (p.Cys500Trp [Cys482Trp]) of exon 13 in the F11 gene. The 
location of the variation is indicated by an arrow. *Conventional 
numbering according to Asakai et al. [6] at the protein level, omit-
ting the signal peptide and counting the start codon ATG as -18.
Abbreviation: Ref sequence, reference DNA sequence.
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tion. Such studies would facilitate the development of a data-
base in order to better identify mutations in Korea and their rela-
tionship with racial and geographical differences.
 Patients with FXI deficiency show a wide spectrum of bleeding 
severity. Patients with severe symptoms (FXI activity <20%) are 
either homozygotes or complex heterozygotes, while those with 
heterozygous mutations usually show no or only minor symptoms 
[4]. The present patient did not have epistaxis, except when the 
allergic rhinitis worsened, and the blood coagulation test results 
were normal except for the prolonged aPTT. The patient was 
found to be a carrier for a mutation that results in a non-synony-
mous amino acid change (Cys482Trp). This mutation affects 
exon 13, which encodes the FXI C-terminal serine protease (SP) 
domain that is important for dissociating the disulfide bond be-
tween the Cys482 and Cys362 residues. This dissociation is fol-
lowed by a change in conformation and reduction in the activa-
tion of FXI [15].
 The F11 gene, located on chromosome 4, consists of 15 ex-
ons and 14 introns and spans 23 kb [5]. To date, the genetic 
tests that have been performed in the Korean patients with FXI 
Table 1. Phenotypic and genotypic results in the Korean patients with FXI deficiency
No. case Age (yr) Sex Reason for referral
FXI:C 
(%)
Zygosity
Mutation information
Codon
(HGVS nomenclature)*
Amino
acid change†
Exon References
1 14 M Epistaxis 26 Hetero c.1500C>G Cys482Trp 13 Present study
2 74 M Bleeding during
   urologic procedure
4 Homo c.841C>T Gln263X‡ 8 [14]
3 51 F History of post-operative
   bleeding
2 Homo c.841C>T Gln263X 8 [14]
4 46 M Pre-operative screening 5 Homo c.841C>T Gln263X 8 [14]
5 7 F Pre-operative screening 53 Hetero c.94G>A Gly14Arg 3 [14]
6 25 M Pre-operative screening 3 Comp
Hetero
c.730C>T
c.755G>C
Gln226X
Arg234Thr
7
7
[14]
7 27 M Health check up 48 Hetero c.688T>C Cys212Arg 7 [14]
8 33 F Pre-operative screening 38 Hetero c.159C>A His35Gln 3 [14]
9 11 M Pre-operative screening 9 Comp
Hetero
c.1546G>A
c.1560dupG
Val498Met
Tyr503ValfsX32
13
13
[14]
10 7 F Pre-operative screening
Epistaxis
39 Hetero c.1201T>C Trp383Arg 11 [14]
11 7 M Pre-operative screening 12 Comp
Hetero
c.730C>T
c.1578C>G
Gln226X
Asp508Glu
7
14
[14]
12 68 F Pre-operative screening 2 Comp
Hetero
c.730C>T
c.1556G>A
Gln226X
Trp501X
[14]
13 22 M Difficulty in bleeding 
   control during nose surgery
20 Hetero c.1253G>T Gly400Val [14]
14 22 F Difficulty in bleeding control
   during plastic surgery
<1 Comp
Hetero
c.841C>T
c.1135+1G>A
Gln263X
NA
8
Splice site
[14]
15 18 F Pre-operative screening 35 Hetero c.1517A>G Asp488Gly 13 [16]
16 33 F Routine gynecologic workup 1 Comp
Hetero
c.1546G>A
c.1560dupG
Val498Met
Tyr503ValfsX32
13
13
[17]
17 10 M Epistaxis 11 Comp
Hetero
c.730C>T
c.1326G>C
Gln226X
Leu424Phe
7
12
[18]
*The approved HGVS nomenclature with ‘A’ of the translation initiation codon ATG numbered as +1 was used to describe nucleotide numbering for coding 
level; †Conventional numbering according to Asakai et al. [6] at the protein level, omitting the signal peptide and counting the start codon ATG as -18; ‡X in 
this column indicates the stop codon.
Abbreviations: Comp Hetero, compound heterozygote; Hetero, heterozygote; HGVS, Human Genome Variation Society; Homo, homozygote; F, female; FXI, 
factor XI; FXI:C, FXI coagulant activity; M, male; NA, not available.
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deficiency were conducted by testing all 15 exons to identify 
mutations. However, in this case, only four exons (7, 8, 11, and 
13) were subjected to sequencing. Since the Q226X and Q263X 
nonsense mutations commonly occur in the Korean patients 
with FXI deficiency. Kim et al. [14] proposed that these patients 
should first be screened for putative mutations affecting exons 7 
and 8. Their study showed that 57.1% of patients had mutations 
in exons 7 and 8, with the detection rate increasing to 71.4% 
when exon 13 was included, and to 80.1% when exon 11 was 
also included. In addition, all the other reported cases where the 
molecular bases of the FXI deficiency were confirmed in the Ko-
rean patients were found to be mutations affecting either exon 7 
[18] or exon 13 [16, 17]. Thus, these findings strongly indicate 
that identification of causative mutations in the Korean patients 
with FXI deficiency should involve initial screening of mutations 
in exons 7, 8, 11, and 13 by sequencing. Sequencing of the ad-
ditional 11 exons is warranted, if the screening results for those 
4 exons are not in line with the patient’s clinical manifestation. 
Furthermore, it would also be efficient in terms of time and cost 
to screen the other exons as well when the clinical manifestation 
is very severe (i.e., FXI activity is severely reduced), which indi-
cates a homozygous or complex heterozygous mutation, but 
only a single heterozygous mutation is identified in one of the 
four most frequently mutated exons. In this case, further screen-
ing was not needed since the patient’s mild clinical manifesta-
tion and FXI coagulation test results were in agreement with the 
finding that the patient was heterozygous for a mutation affect-
ing exon 13.
 In summary, we identified the Cys482Trp missense mutation 
in a Korean patient with FXI deficiency. Owing to the small num-
ber of FXI deficiency cases with associated mutations that have 
been reported in Korea to date, further studies are warranted to 
contribute to the development of a database that would help 
clarify the distribution of mutations present in the Korean popu-
lation. Such a database would also facilitate studies aimed to 
clarify the possibility of a founder effect for F11 gene mutations. 
Furthermore, these efforts would help improve the molecular 
and genetic diagnostic strategies used for the Korean patients.
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